Ischemic Heart Disease (IHD) Drugs Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What are the Key Projections for the CAGR of the Ischemic Heart Disease (IHD) Drugs Market From 2025 to 2034?
The market for drugs treating ischemic heart disease (IHD) has experienced significant growth in recent times. The market which stands at $6.36 billion in 2024 is projected to reach $6.71 billion in 2025 with a compound annual growth rate (CAGR) of 5.6%. This past growth has occurred due to factors such as the increasing global incidents of ischemic heart disease, better awareness and diagnostics, changes in lifestyle and dietary habits, government policies supporting cardiovascular health, collaborations to conduct clinical trials, and insurance coverage and reimbursement policies.
The market size for drugs used in the treatment of ischemic heart disease (IHD) is predicted to experience constant growth in the upcoming years. It is forecasted to reach $7.86 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.0%. The forecast period’s growth can be ascribed to factors such as the increasing age of the population, tailored medicine strategies, focus on cardiovascular prevention, worldwide healthcare policies and ventures, and global research partnerships. Key trends projected for this period incorporate a shift towards precision medicine methods, a concentrated effort on new anti-atherogenic agents, advancements in the domain of lipid-reducing therapies, the incorporation of anti-inflammatory agents, as well as the evolution of antithrombotic and antiplatelet drugs.
What Key Drivers Are Accelerating the Growth of the ischemic heart disease (ihd) drugs Market During the Forecast Period?
The Ischemic Heart Disease (IHD) drugs market is anticipated to grow due to the rising prevalence of obesity and diabetes worldwide. Diabetes, a sustained metabolic disorder, elevates blood glucose levels, while obesity engenders an excess buildup of body fat, which can cause various health issues. IHD drugs are commonly prescribed to obese and diabetic individuals to control cardiovascular risk factors including hypertension and dyslipidemia, reducing the likelihood of ischemic heart disease. For example, the UK-based World Obesity Federation reported in 2022 that by 2030, one billion people globally, encompassing 1 in 5 women and 1 in 7 men, will be obese. The National Health Service, another UK-based government department, announced in June 2024 that in 2023, over half a million (549,000) additional individuals were at risk of type 2 diabetes, elevating the total number of those with pre-diabetes registered with a GP to 3,615,330. This is a considerable rise compared to 3,065,825 in 2022, marking a nearly 20% increase. This growing prevalence of diabetes and obesity thus facilitates the expansion of the Ischemic Heart Disease drugs market. The projected surge in heart failure cases is another impelling factor for the growth of the Ischemic Heart Disease (IHD) drugs market. Heart failure, a persistent condition in which the heart cannot sufficiently pump blood to satisfy the body’s necessities for blood and oxygen, is the root cause of fatigue, breathing difficulty, and performance hindrance in daily activities. IHD drugs are pivotal in the treatment of heart failure, as they mitigate risk factors and symptoms, thus preventing heart failure. These medicaments curtail the heart’s pacemaker activity and greatly benefit heart failure patients with decreased ejection fractions and elevated resting heart rates after tolerating a beta-blocker. In September 2023, according to the US-based Heart Failure Society of America, an estimated 6.7 million Americans aged over 20 years had heart failure, and the number is set to ascend to 8.5 million Americans by 2030. Consequently, the increasing rate of heart failure contributes significantly to the growth of the Ischemic Heart Disease drug market.
Request Your Free Ischemic Heart Disease (IHD) Drugs Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
What Are the Key Industry Players Leading the Charge in the Ischemic Heart Disease (IHD) Drugs Market’s Growth?
Major companies operating in the ischemic heart disease (ihd) drugs market report are:
• Pfizer Inc._x000D_
• F. Hoffmann-La Roche Ltd._x000D_
• Merck & Co. Inc._x000D_
• AbbVie Inc._x000D_
• Bayer AG_x000D_
How Are Market Trends and Shifts Impacting the Growth Trajectory of the Ischemic Heart Disease (IHD) Drugs Market?
Leading firms in the ischemic heart disease (IHD) drugs market, such as Bristol Myers Squibb, are striving to develop cutting-edge myosin inhibitors, aiming to secure a competitive advantage in the market. Myosin inhibitors are beneficial for conditions like hypertrophic cardiomyopathy (HCM) since these drugs lessen myosin activity in the heart muscle, thereby diminishing contraction force. These drugs are especially needed when the heart muscle becomes excessively thick and affects heart functioning. For instance, in April 2022, the US-based pharmaceutical company, Bristol Myers Squibb, introduced Camzyos (mavacamten). This new drug, the first of its kind as a cardiac myosin inhibitor, is authorized for the treatment of adults showing symptoms of new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM). Camzyos proves effective in enhancing functional capacity and symptoms by acting as an allosteric and reversible inhibitor selective for cardiac myosin. This action serves to mitigate hypercontractility and left ventricular hypertrophy while bettering cardiac filling pressures, helping to alleviate dynamic left ventricular outflow tract (LVOT) obstruction.
Pre-order Your Report for Quick and Easy Delivery!
Which Growth-Oriented Segments of the Ischemic Heart Disease (IHD) Drugs Market Are Leading the Industry’s Development?
The ischemic heart disease (IHD) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
What Regions Are Influencing the Dynamics of the Ischemic Heart Disease (IHD) Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Scope and Reach of the Ischemic Heart Disease (IHD) Drugs Market Defined?
Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.
Browse Through More Similar Reports By The Business Research Company:
Narcotic Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report
Preeclampsia Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report
Congenital Diaphragmatic Hernia Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
